BioWorld

Oct. 28, 2004

View Archived Issues

Although Vioxx Troubled, Cox-2 Area Still Of Interest

Read More

FDA Approves Shire's Phosphate Binder Fosrenol In Renal Disease

Read More

Other News To Note

Read More

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More

Paratek, Serono In $38M-Plus Collaboration For MS Drugs

Read More